ZyMedBio Corp is a pharmaceutical development company. The company is relatively new, having been incorporated just three years ago. In the last five months, the company has begun drug trials on human subjects for a range of clinical issues. Currently, ZyMedBio is undertaking a Phase 2 study where human subjects are being given doses of a new drug called “Zylactis.”

Behind a miraculous cure for many ills hides a loathsome truth.